VeraSci and AiCure collaborated on this case study about the methods they used to continue data collection for a schizophrenia trial during the COVID-19 pandemic.
When a phase II schizophrenia study for patients with cognitive impairment was faced with fewer patients able to attend in-person study visits because of COVID-19, the sponsor needed solutions to help them navigate remote engagement and assessment.
AiCure and VeraSci employed innovative solutions to keep this global trial on track:
- Reduced patient-burden with simple and easy-to-use technology for dosing support
- Transitioned in-person assessments to remote assessments
- Employed digital biomarkers to complement clinical assessments